Prot #NU JH24N02: Neoadjuvant Pembrolizumab and IO102-IO103 Prior to Curative-Intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN): The KIEO Trial

Project: Research project

Project Details

StatusActive
Effective start/end date1/2/25 → 5/31/27

Funding

  • Johns Hopkins University (Prot #NU JH24N02 // Prot #NU JH24N02)
  • Merck Sharp & Dohme Corporation (Prot #NU JH24N02 // Prot #NU JH24N02)